Longitudinal Persistence of Meningeal Enhancement on Postcontrast 7T 3D-FLAIR MRI in Multiple Sclerosis

References

1. 1.↵
   2. Magliozzi R,
   3. Howell O,
   4. Vora A, et al

   . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain J Neurol 2007;130(Pt 4):1089–104 pmid:17438020

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Lucchinetti CF,
   3. Popescu BF,
   4. Bunyan RF, et al

   . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97 doi:10.1056/NEJMoa1100648 pmid:22150037

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Choi SR,
   3. Howell OW,
   4. Carassiti D, et al

   . Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain J Neurol 2012;135(Pt 10):2925–37 doi:10.1093/brain/aws189 pmid:22907116

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Serafini B,
   3. Rosicarelli B,
   4. Magliozzi R, et al

   . Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164–74 doi:10.1111/j.1750-3639.2004.tb00049.x pmid:15193029

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Kowarik MC,
   3. Cepok S,
   4. Sellner J, et al

   . CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 2012;9:93 doi:10.1186/1742-2094-9-93 pmid:22591862

   CrossRefPubMed
6. 6.↵
   2. Nielsen AS,
   3. Kinkel RP,
   4. Tinelli E, et al

   . Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging 2012;35:537–42 doi:10.1002/jmri.22847 pmid:22045554

   CrossRefPubMed
7. 7.↵
   2. Absinta M,
   3. Vuolo L,
   4. Rao A, et al

   . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18–28 doi:10.1212/WNL.0000000000001587 pmid:25888557

   Abstract/FREE Full Text
8. 8.↵
   2. Zivadinov R,
   3. Ramasamy DP,
   4. Hagemeier J, et al

   . Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol 2018;39:642–47 doi:10.3174/ajnr.A5541 pmid:29439125

   Abstract/FREE Full Text
9. 9.↵
   2. Harrison DM,
   3. Wang KY,
   4. Fiol J, et al

   . Leptomeningeal enhancement at 7T in multiple sclerosis: frequency, morphology, and relationship to cortical volume. J Neuroimaging 2017;27:461–68 doi:10.1111/jon.12444 pmid:28464368

   CrossRefPubMed
10. 10.↵
    2. Howell OW,
    3. Reeves CA,
    4. Nicholas R, et al

    . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain J Neurol 2011;134(Pt 9):2755–71 doi:10.1093/brain/awr182 pmid:21840891

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Howell OW,
    3. Schulz-Trieglaff EK,
    4. Carassiti D, et al

    . Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol Appl Neurobiol 2015;41:798–813 doi:10.1111/nan.12199 pmid:25421634

    CrossRefPubMed
12. 12.↵
    2. Polman CH,
    3. Reingold SC,
    4. Banwell B, et al

    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Haines K,
    3. Smith NB,
    4. Webb AG

    . New high dielectric constant materials for tailoring the B1+ distribution at high magnetic fields. J Magn Reson 2010;203:323–27 doi:10.1016/j.jmr.2010.01.003 pmid:20122862

    CrossRefPubMed
14. 14.↵
    2. Marques JP,
    3. Kober T,
    4. Krueger G, et al

    . MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage 2010;49:1271–81 doi:10.1016/j.neuroimage.2009.10.002 pmid:19819338

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Tustison NJ,
    3. Avants BB,
    4. Cook PA, et al

    . N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010;29:1310–20 doi:10.1109/TMI.2010.2046908 pmid:20378467

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52 doi:10.1212/WNL.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
17. 17.↵
    Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Paralyzed Veterans of America 1998:1–33
18. 18.↵
    2. Flachenecker P,
    3. Kumpfel T,
    4. Kallmann B, et al

    . Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8:523–26 doi:10.1191/1352458502ms839oa pmid:12474995

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Smith A

    . Symbol Digit Modalities Test: Manual. Los Angeles: Western Psychological Services; 1973
20. 20.↵
    2. Aspelund A,
    3. Antila S,
    4. Proulx ST, et al

    . A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 2015;212:991–99 doi:10.1084/jem.20142290 pmid:26077718

    Abstract/FREE Full Text
21. 21.↵
    2. Raper D,
    3. Louveau A,
    4. Kipnis J

    . How do meningeal lymphatic vessels drain the CNS? Trends Neurosci 2016;39:581–86 doi:10.1016/j.tins.2016.07.001 pmid:27460561

    CrossRefPubMed
22. 22.↵
    2. Absinta M,
    3. Ha SK,
    4. Nair G, et al

    . Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elif 2017;6 doi:10.7554/eLife.29738 pmid:28971799

    CrossRefPubMed
23. 23.↵
    2. Plog BA,
    3. Nedergaard M

    . The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol 2018;13:379–94 doi:10.1146/annurev-pathol-051217-111018 pmid:29195051

    CrossRefPubMed
24. 24.↵
    2. Ortiz GG,
    3. Pacheco-Moisés FP,
    4. Macías-Islas MA, et al

    . Role of the blood-brain barrier in multiple sclerosis. Arch Med Res 2014;45:687–97 doi:10.1016/j.arcmed.2014.11.013 pmid:25431839

    CrossRefPubMed
25. 25.↵
    2. Zivadinov R,
    3. Ramasamy DP,
    4. Vaneckova M, et al

    . Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler 2017;23:1336–45 doi:10.1177/1352458516678083 pmid:27811339

    CrossRefPubMed
26. 26.↵
    2. Absinta M,
    3. Cortese IC,
    4. Vuolo L, et al

    . Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017;88:1439–44 doi:10.1212/WNL.0000000000003820 pmid:28283598

    Abstract/FREE Full Text